A New Frontier: Targeting Viral Remnants in Neurodegeneration
A groundbreaking study in *Brain* demonstrates a novel gene therapy approach for amyotrophic lateral sclerosis (ALS) by targeting human endogenous retrovirus-K (HERV-K). Researchers used an adeno-associated virus-9 (AAV9) vector to deliver artificial microRNAs (amiRNAs) that specifically silenced the HML-2 *env* gene, a component of HERV-K implicated in neurotoxicity. In a transgenic mouse model of ALS, a single early injection effectively reduced HML-2 Env protein levels in the central nervous system for over 12 weeks. This targeted knockdown preserved cortical and spinal motor neurons, reduced muscle pathology, and led to significant improvements in motor function, offering compelling preclinical evidence for a new therapeutic strategy in forms of ALS linked to this viral element.
Study Significance: For hepatology, this research is methodologically adjacent but highly instructive. It showcases the potent application of AAV-mediated gene silencing, a platform technology rapidly advancing in liver-targeted therapies for metabolic diseases like familial hypercholesterolemia and amyloidosis. The success of tandem amiRNA design for robust, sustained knockdown of a pathogenic protein directly informs strategies for treating liver fibrosis or hepatocellular carcinoma driven by specific genetic drivers. This study underscores the translational potential of precise nucleic acid therapies, a paradigm directly relevant to next-generation treatments for chronic liver disease where modulating gene expression is a key therapeutic goal.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
